Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
BillionToOne, Inc. Chief Product Officer Sakakibara Shan Riku reported open-market sales of 8,000 shares of Class A Common Stock on June 8, 2026. The transactions were executed in two tranches at prices of $100.00 and $96.45 per share under a pre-arranged Rule 10b5-1 trading plan.
The filing indicates these were routine, pre-planned dispositions, and the executive continues to hold a substantially larger direct equity position after the sales.
BillionToOne, Inc. officer Nancy JoAnn Johnson reported open-market sales of 14,000 shares of Class A Common Stock on June 8–9, 2026. The shares were sold in seven transactions at weighted-average prices generally around $99–$102 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026.
BillionToOne, Inc. director and officer Atay Oguzhan reported multiple transactions in the company’s Class A and Class B common stock. On June 8, 2026, he acquired a total of 36,250 shares of Class A common stock through option exercises and conversion of Class B shares at prices from $0.00 to $2.80 per share.
That same day, 38,750 shares of Class A common stock were sold in open-market transactions at weighted-average prices ranging from about $94.30 to $100.87, including sales of shares held by his spouse. On June 9, 2026, he made a bona fide gift of 10,000 Class A shares. The transactions were effected under a Rule 10b5-1 trading plan adopted on March 6, 2026.
BLLN affiliate files Form 144 to report proposed resale of Class A shares. The notice lists multiple blocks of Pre-IPO Class A shares dated 01/07/2020, 05/05/2020, and 07/03/2020 totaling discrete lots of 6,582, 3,200, and 800 shares respectively. The filing also discloses a sale in the past three months by Nancy J. Johnson of 3,418 Class A shares for $339,347.28 on 06/08/2026.
NeoTribe-affiliated funds and entities, each a 10% owner of BillionToOne, Inc., reported internal restructuring transactions in Class A Common Stock. On May 11, 2026, they executed J-code “other” transactions totaling 465,607 shares, classified as pro-rata, in-kind distributions to partners and members for no additional consideration.
These moves shifted shares among related funds and their investors at a stated price of $0.00 per share, changing how holdings are allocated between direct and indirect ownership but not reflecting open-market purchases or sales of BLLN stock.